Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Cash from Financing Activities for 10 consecutive years, with -$5.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 116.62% year-over-year to -$5.4 million; the TTM figure through Mar 2026 stood at $180.1 million (down 17.97% YoY), while the FY2025 annual figure was $218.0 million, up 13.97% from the prior year.
• Cash from Financing Activities fell to -$5.4 million in Q1 2026 per RYTM's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $189.3 million in Q3 2025 and bottomed at -$5.4 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $40.7 million across 5 years, with a median of $4.2 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 38293.22% — and 2023, when it slumped 133.33%.
• Rhythm Pharmaceuticals' Cash from Financing Activities stood at $17.4 million in 2022, then sank by 86.05% to $2.4 million in 2023, then soared by 1481.84% to $38.3 million in 2024, then slumped by 107.69% to -$2.9 million in 2025, then plunged by 83.18% to -$5.4 million in 2026.
• Business Quant data shows RYTM's Cash from Financing Activities at -$5.4 million in Q1 2026, -$2.9 million in Q4 2025, and $189.3 million in Q3 2025.